Regression of central giant cell granuloma by a combination of imatinib and interferon: a case report.
Central giant cell granuloma is a benign lesion of the jaws which is sometimes aggressive locally. The most common treatment is curettage,which has a high recurrence rate, particularly in more aggressive lesions. Other treatments such as interferon (IFN) and calcitonin have been described. We report a patient with Stickler syndrome and an aggressive central giant cell granuloma in the mandible. Initial treatment with calcitonin was not successful. A combination of IFN and imatinib, given for 9 months, initiated regression of the lesion that continued after treatment had ceased.
de Lange
Jan
J
Department of Oral and Maxillofacial Surgery, Academic Medical Center and Academic Center for Dentistry (ACTA), University of Amsterdam, The Netherlands.
van Rijn
Rick R
RR
van den Berg
Henk
H
van den Akker
Hans P
HP
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002116:Calcitonin / Q000627:therapeutic use; D003095:Collagen Diseases / Q000139:chemically induced*; D004338:Drug Combinations; D005260:Female; D006101:Granuloma, Giant Cell / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008336:Mandibular Diseases / Q000150:complications / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011994:Recombinant Proteins; D012074:Remission Induction; D013577:Syndrome
D000970:Antineoplastic Agents; D001549:Benzamides; D004338:Drug Combinations; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000068877:Imatinib Mesylate; D002116:Calcitonin; C100416:peginterferon alfa-2a